Rameda to offer up to 45% of its shares on EGX
IPO WATCH- Pharma manufacturer Rameda is planning to list up to 45% of the company’s shares on the EGX, sources close to the transaction tell us in the wake of a report in Al Mal on Thursday. Expect the EGP 1.9-2.3 bn transaction to include both primary and secondary sales that will see 35-45% of the company in free float. The transaction will include both a domestic retail offering and an international institutional offering, we’re told.
Advisers: CI Capital will be joint global coordinator and sole bookrunner, while Compass Capital will be joint global coordinator and lead manager. Zaki Hashem has been tapped to serve as counsel to the underwriters. Norton Rose Fulbright will be international counsel to the issuer, with Matouk Bassiouny doing domestic duties. E&Y is Rameda’s auditor, while the lead on Rameda’s IFA has yet to be appointed.